(Q40233983)

18 September 2017

Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route (English)

1 reference

18 September 2017

Cheng-Fen Tu

1

1 reference

18 September 2017

Chi-Chen Lin

2

1 reference

18 September 2017

Ming-Chuan Chen

3

1 reference

18 September 2017

Tai-Ming Ko

4

1 reference

18 September 2017

Chiu-Mei Lin

5

1 reference

18 September 2017

Ying-Chang Wang

6

1 reference

18 September 2017

Ming-Derg Lai

7

1 reference

18 September 2017

language of work or name

English

0 references

publication date

22 August 2006

1 reference

18 September 2017

1 reference

18 September 2017

25

1 reference

18 September 2017

4

1 reference

18 September 2017

719-728

1 reference

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

18 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

ErbB2 is essential in the prevention of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

DNA-based immunization by in vivo transfection of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Cellular mechanisms governing cross-presentation of exogenous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Immune recognition of self in immunity against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

The "grand" problem of synthetic delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.009

10.1016/J.VACCINE.2006.08.009

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference